SCHEMBL5596147

SCHEMBL5596147

CCCCCNc1sc(N)nc1CCCCC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 9/20 0.41
TLR7 Q9NYK1 4/20 0.41
ALDH1A1 P00352 2/20 0.40
KCNH3 Q9ULD8 1/20 0.39
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
STAT1 P42224 1/20 0.38
MMP3 P08254 1/20 0.36
KMT2A Q03164 1/20 0.36
DHFR P00374 1/20 0.35
ADRB2 P07550 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
ADRB1 P08588 1/20 0.35
HTR1A P08908 1/20 0.35
CHRM5 P08912 1/20 0.35
ADRA2A P08913 1/20 0.35
CHRM1 P11229 1/20 0.35
DRD2 P14416 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16498140 0.73 ALDH1A1 (0.44) TLR8TLR7ALDH1A1RAB9AKMT2A
SCHEMBL11338473 0.69 GABRP (0.45) ALDH1A1MAPTDHFRADRB2CHRM2
SCHEMBL7186350 0.69 ALDH1A1 (0.41) TLR8TLR7ALDH1A1RAB9AKMT2A
SCHEMBL10358696 0.69 ALDH1A1 (0.41) TLR8TLR7ALDH1A1RAB9ADHFR
SCHEMBL10358694 0.68 ALDH1A1 (0.40) ALDH1A1RAB9AKMT2ADHFRKDM4E
SCHEMBL28917013 0.67 KCNH3 (0.44) TLR8TLR7KCNH3MAPTKMT2A
SCHEMBL1101351 0.67 ALDH1A1 (0.39) ALDH1A1RAB9ANPC1MAPTKMT2A
SCHEMBL19594200 0.66 KCNH3 (0.54) TLR8TLR7ALDH1A1KCNH3RAB9A
SCHEMBL514975 0.66 KCNH3 (0.63) ALDH1A1KCNH3MAPTKMT2A
SCHEMBL11325593 0.66 ALDH1A1 (0.41) ALDH1A1RAB9ANPC1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032521-A1 Use of c-kit inhibitors for treating type II diabetes AB SCIENCE 2007-02-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032521-A1 Use of c-kit inhibitors for treating type II diabetes KIT, CPA3, CMA1 TLR8 2951/4885TLR7 1475/4885ALDH1A1 1266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.